Literature DB >> 11935462

Mutation in loop I of VP1 of Theiler's virus delays viral RNA release into cells and enhances antibody-mediated neutralization: a mechanism for the failure of persistence by the mutant virus.

Ingeborg J McCright1, Ikuo Tsunoda, Jane E Libbey, Robert S Fujinami.   

Abstract

The DA strain of Theiler's murine encephalomyelitis viruses (TMEV) causes a central nervous system (CNS) demyelinating disease with viral persistence despite the presence of high serum anti-TMEV antibody titers. The DA virus mutant, T81D, was created to have a mutation at position 81 in loop I of VP1, close to the putative virus receptor binding site. T81D showed slower replication in vitro and in vivo. T81D-infected mice developed anti-TMEV antibody responses with no virus persistence. We tested whether the differences between the viruses were due to alteration in virus-cell interactions, or in the resistance to neutralization by anti-TMEV antibody. Using radiolabeled viruses, we found no difference in binding to permissive cell lines between the mutant and wild-type viruses. In a semipermissive cell line, DA virus bound more efficiently than T81D. During the uncoating step, both viruses decapsidated without the production of stable intermediates and 80% of viruses were eluted or decapsidated after 45 minutes. At the final step of uncoating, however, T81D showed a slower rate of RNA release than DA virus into cells using a photoinactivation assay. Anti-TMEV monoclonal and polyclonal antibodies neutralized T81D virus more efficiently than DA virus in suspension. Further, these anti-TMEV antibodies were able to neutralize viruses that had already attached to cells but not internalized (postadsorption neutralization [PAN]). However, DA virus showed significant resistance to PAN after cells were incubated at 37 degrees C compared with T81D-infected cells. The development of resistance to PAN appeared to correlate with the rate of RNA release from virions into cells. In T81D virus infection, the slow RNA release and high susceptibility to neutralization by antibodies would result in a failure to establish virus persistence in vivo. Conversely, rapid RNA release and resistance to neutralization could favor virus persistence in DA virus infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11935462     DOI: 10.1080/13550280290049561

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  34 in total

1.  ASPECTS OF THE GROWTH OF POLIOVIRUS AS REVEALED BY THE PHOTODYNAMIC EFFECTS OF NEUTRAL RED AND ACRIDINE ORANGE.

Authors:  J N WILSON; P D COOPER
Journal:  Virology       Date:  1963-10       Impact factor: 3.616

Review 2.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

3.  Interaction of liposomes with subviral particles of poliovirus type 2 and rhinovirus type 2.

Authors:  K Lonberg-Holm; L B Gosser; E J Shimshick
Journal:  J Virol       Date:  1976-08       Impact factor: 5.103

4.  Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.

Authors:  K Kirkegaard
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

5.  SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.

Authors:  B Rosenwirth; D A Oren; E Arnold; Z L Kis; H J Eggers
Journal:  Antiviral Res       Date:  1995-01       Impact factor: 5.970

6.  Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases.

Authors:  H W Virgin; M A Mann; K L Tyler
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Characterization of the ion channels formed by poliovirus in planar lipid membranes.

Authors:  M T Tosteson; M Chow
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Neutralization of poliovirus by cell receptors expressed in insect cells.

Authors:  G Kaplan; M S Freistadt; V R Racaniello
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

9.  Theiler's murine encephalomyelitis virus-binding activity on neural and non-neural cell lines and tissues.

Authors:  N Rubio; C De Felipe; C Torres
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

10.  Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system.

Authors:  K L Tyler; H W Virgin; R Bassel-Duby; B N Fields
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  5 in total

1.  Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Authors:  Ikuo Tsunoda; Fumitaka Sato; Seiichi Omura; Mitsugu Fujita; Namie Sakiyama; Ah-Mee Park
Journal:  Clin Exp Neuroimmunol       Date:  2016-10-25

2.  Infectious RNA isolated from the spinal cords of mice chronically infected with Theiler's murine encephalomyelitis virus.

Authors:  Jane E Libbey; Ikuo Tsunoda; J Lindsay Whitton; Robert S Fujinami
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

3.  An elite controller of picornavirus infection targets an epitope that is resistant to immune escape.

Authors:  Michael P Bell; Danielle N Renner; Aaron J Johnson; Kevin D Pavelko
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 4.  Viral mouse models used to study multiple sclerosis: past and present.

Authors:  J E Libbey; R S Fujinami
Journal:  Arch Virol       Date:  2021-02-13       Impact factor: 2.685

5.  Theiler's murine encephalomyelitis virus attachment to the gastrointestinal tract is associated with sialic acid binding.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neurovirol       Date:  2008-12-26       Impact factor: 2.643

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.